Overall survival in MERiDiAN, a double-blind placebo-controlled randomised phase III trial evaluating first-line bevacizumab plus paclitaxel for HER2-negative metastatic breast cancer

被引：14

作者：

Miles, David ^{[1
]}

Cameron, David ^{[2
,3
]}

Hilton, Magalie ^{[4
]}

Garcia, Josep ^{[5
]}

O'Shaughnessy, Joyce ^{[6
]}

机构：

[1] Mt Vernon Canc Ctr, Rickmansworth Rd, London HA6 2RN, England

[2] Univ Edinburgh, Crewe Rd South, Edinburgh EH4 2XU, Midlothian, Scotland

[3] Western Gen Hosp, NHS Lothian, Canc Serv, Crewe Rd South, Edinburgh EH4 2XU, Midlothian, Scotland

[4] F Hoffmann La Roche Ltd, Pharma Dev, Biostat Oncol, Bldg 663,Hochstr, CH-4070 Basel, Switzerland

[5] F Hoffmann La Roche Ltd, Prod Dev Oncol, Grenzacherstr 124, CH-4070 Basel, Switzerland

[6] US Oncol & Texas Oncol, Baylor Charles A Sammons Canc Ctr, 3410 Worth St,Suite 400, Dallas, TX 75246 USA

来源：

EUROPEAN JOURNAL OF CANCER | 2018年 / 90卷

关键词：

PROGRESSION-FREE SURVIVAL; SURROGATE; THERAPY;

D O I：

10.1016/j.ejca.2017.10.018

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：153 / 155

页数：3

共 8 条

[1] Correlation between progression-free survival and overall survival in metastatic breast cancer patients receiving anthracyclines, taxanes, or targeted therapies: a trial-level meta-analysis
Adunlin, George
Cyrus, John W. W.
Dranitsaris, George
[J]. BREAST CANCER RESEARCH AND TREATMENT, 2015, 154 (03) : 591 - 608
[2] Detecting an Overall Survival Benefit that Is Derived From Progression-Free Survival
Broglio, Kristine R.
Berry, Donald A.
[J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2009, 101 (23): : 1642 - 1649
[3] Progression-Free Survival as a Surrogate for Overall Survival in Clinical Trials of Targeted Therapy in Advanced Solid Tumors
Michiels, Stefan
Saad, Everardo D.
Buyse, Marc
[J]. DRUGS, 2017, 77 (07) : 713 - 719
[4] Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation
Miles, David
Cameron, David
Bondarenko, Igor
Manzyuk, Lyudmila
Alcedo, Juan Carlos
Lopez, Roberto Ivan
Im, Seock-Ah
Canon, Jean-Luc
Shparyk, Yaroslav
Yardley, Denise A.
Masuda, Norikazu
Ro, Jungsil
Denduluri, Neelima
Hubeaux, Stanislas
Quah, Cheng
Bais, Carlos
O'Shaughnessy, Joyce
[J]. EUROPEAN JOURNAL OF CANCER, 2017, 70 : 146 - 155
[5] Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer
Miles, David W.
Chan, Arlene
Dirix, Luc Y.
Cortes, Javier
Pivot, Xavier
Tomczak, Piotr
Delozier, Thierry
Sohn, Joo Hyuk
Provencher, Louise
Puglisi, Fabio
Harbeck, Nadia
Steger, Guenther G.
Schneeweiss, Andreas
Wardley, Andrew M.
Chlistalla, Andreas
Romieu, Gilles
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (20) : 3239 - 3247
[6] Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
Miller, Kathy
Wang, Molin
Gralow, Julie
Dickler, Maura
Cobleigh, Melody
Perez, Edith A.
Shenkier, Tamara
Cella, David
Davidson, Nancy E.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (26) : 2666 - 2676
[7] RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative, Locally Recurrent or Metastatic Breast Cancer
Robert, Nicholas J.
Dieras, Veronique
Glaspy, John
Brufsky, Adam M.
Bondarenko, Igor
Lipatov, Oleg N.
Perez, Edith A.
Yardley, Denise A.
Chan, Stephen Y. T.
Zhou, Xian
Phan, See-Chun
O'Shaughnessy, Joyce
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (10) : 1252 - 1260
[8] Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature
Saad, E. D.
Katz, A.
Hoff, P. M.
Buyse, M.
[J]. ANNALS OF ONCOLOGY, 2010, 21 (01) : 7 - 12

← 1 →